Old Web
English
Sign In
Acemap
>
authorDetail
>
Tateo Endo
Tateo Endo
non-small cell lung cancer (NSCLC)
Oncology
Erlotinib
Pathology
Epidermal growth factor receptor
2
Papers
42
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
2017
Journal of Clinical Oncology
Yoshio Okano
Masahiko Ando
Kazuhiro Asami
Masaaki Fukuda
Hideyuki Nakagawa
Hidenori Ibata
Toshiyuki Kozuki
Tateo Endo
Atsuhisa Tamura
Mitsuhiro Kamimura
Kazuhiro Sakamoto
Michihiro Yoshimi
Yoshifumi Soejima
Yoshio Tomizawa
Shun Ichi Isa
Minoru Takada
Hideo Saka
Akihito Kubo
Tomoya Kawaguchi
Show All
Source
Cite
Save
Citations (39)
Updated overall survival (OS) results of randomized phase III trial of erlotinib (E) versus (v) docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
2014
Journal of Clinical Oncology
Hidenori Ibata
Masahiko Ando
Kazuhiro Asami
Yoshio Okano
Masaaki Fukuda
Hideyuki Nakagawa
Toshiyuki Kozuki
Tateo Endo
Atsuhisa Tamura
Mitsuhiro Kamimura
Kazuhiro Sakamoto
Michihiro Yoshimi
Yoshifumi Soejima
Yoshio Tomizawa
Shun Ichi Isa
Minoru Takada
Hideo Saka
Akihito Kubo
Tomoya Kawaguchi
Show All
Source
Cite
Save
Citations (3)
1